countify
No-code computer vision for labs to automate AI image analysis workflows for any experiment and organism.
Website: https://www.countifybio.com/
Cover Block
Publicly reported
| Name | countify |
| Tagline | No-code computer vision for labs to automate AI image analysis workflows for any experiment and organism. |
| Headquarters | Berlin, Germany |
| Founded | 2017 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
Note: Capitalization is not publicly disclosed. An estimated valuation of $3.9M is reported by a third-party directory [GetLatka].
Links
Publicly reported
A direct link to the company's primary product platform is available, though other common social media or developer channels are not publicly confirmed.
- Website: https://www.countifybio.com/
- LinkedIn: https://www.linkedin.com/company/countify/
Summary and Signal
Publicly reported
Countify GmbH offers a no-code computer vision platform that automates image analysis for biological research, a process that remains largely manual and time-consuming in academic and industrial labs [countifybio.com, retrieved 2024]. The company's core proposition is to accelerate discovery by allowing researchers, without coding expertise, to build and deploy AI models that detect and quantify specimens from microscope images in real time [countifybio.com, retrieved 2024]. Founded in 2017 by Cristian Alzati, the Berlin-based SaaS company appears to have evolved from a predecessor entity, Sayula Engineering AG, suggesting a multi-year development cycle for its underlying technology [The Org, retrieved 2026]. Alzati, who studied at Stanford University and Universidad Iberoamericana, serves as the technical lead, holding titles of CTO, Co-Founder, and Lead Software Architect across various public profiles [Crunchbase, LinkedIn, retrieved 2026].
Public capitalization details are sparse; no formal funding rounds with disclosed amounts or investors have been verified, though a third-party service estimates a valuation of $3.9 million [GetLatka]. The business model is a pay-as-you-go SaaS, targeting both academic institutions and biotech/pharma labs with promises of significant efficiency gains, including 95% detection accuracy and processing speeds 120 times faster than manual methods [countifybio.com, retrieved 2024]. Over the next 12-18 months, investor attention should focus on validating the company's customer traction claims, particularly its listed affiliations with major research universities, and monitoring for any disclosed institutional funding that would signal external validation of its commercial progress.
One source, partially checked -- Core product description is confirmed by the company website, but key traction and funding metrics lack independent verification.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed |
Company Overview
Publicly reported
Founded in 2017, countify GmbH is a Berlin-based software company that emerged from the work of its predecessor, Sayula Engineering AG [The Org, retrieved 2026]. The company's core proposition, a no-code computer vision platform for laboratory image analysis, appears to have evolved from an earlier server-based machine called "Anima" developed by that prior entity [The Org, retrieved 2026]. The founder and public face of the company is Cristian Alzati, who is listed across sources as CEO, CTO, and Lead Software Architect [GetLatka, Unknown] [Crunchbase, Unknown] [LinkedIn, retrieved 2026].
A key point of public record clarification involves the company's name. Research indicates at least two distinct businesses operate under the "Countify" brand. The subject of this report is countify GmbH, the Berlin software firm. A separate entity, Countify Capital, LLC, is a U.S.-based capital-management business associated with founder Amity Mercado and has no verified operational connection to the German company [Artis, May 2026]. This distinction is necessary to avoid conflating the two entities' activities, funding, and teams.
Public milestones are sparse. The company's website lists a roster of academic institutions, including Harvard Medical School and Stanford University, under a "TRUSTED BY" banner, though specific customer deployments or partnership dates are not provided [countifybio.com, retrieved 2024]. The most recent verifiable public activity is a presentation given by founder Cristian Alzati for 'The Wheel' Group in July 2026 [awalkinthephysical.com, 2026]. No public funding rounds, acquisitions, or major product launch announcements have been independently verified.
One source, partially checked -- Founding date and founder identity corroborated by multiple directories; entity distinction and milestone details rely on limited public sources.
The Product and the Stack
Public record plus analysis
The core proposition is a no-code platform that allows laboratory researchers to automate image analysis without writing software. The company's website describes a system where users can build, train, and deploy custom computer vision models for any biological specimen or experimental setup [countifybio.com, retrieved 2024]. The workflow is presented as a three-step process: capture an image, analyze it through automated segmentation and counting, and then log the results into a report. A key differentiator claimed is the platform's ability to function as a "visual intelligence agent," processing images in real-time as they are generated by lab equipment [countifybio.com, retrieved 2024].
Technical performance claims are sourced directly from the company. The platform is said to reduce manual work costs by 50%, achieve 95% detection accuracy, and operate 120 times faster than manual processes [countifybio.com, retrieved 2024]. The business model is a pay-as-you-go SaaS subscription, with tailored portals for academic and industrial users. Academic features focus on report generation for publications, while the industry version adds advanced analytics and tools for regulatory compliance reporting [countifybio.com, retrieved 2024].
Public information does not detail the underlying technology stack, model architectures, or data annotation processes. The website emphasizes a "zero coding, zero annotations" approach, suggesting the platform may use techniques like few-shot learning or synthetic data generation to minimize manual setup, though this is an inference from the marketing claim. No public roadmap for future product features or integrations was identified in the available sources.
One source, partially checked -- Product description is confirmed by the company website; performance and speed claims are company-sourced and not independently verified.
The Market They Are Entering
Publicly reported
Automating manual image analysis in life sciences research is a persistent, high-value problem, but the market for a dedicated no-code platform is fragmented and difficult to size directly.
A precise TAM for no-code computer vision in academic and industrial labs is not established in public sources. The broader adjacent market for life sciences AI software is frequently cited, with one report from Grand View Research estimating the global market at $1.2 billion in 2023 and projecting a compound annual growth rate of 19.8% through 2030 [Grand View Research, 2024]. This figure encompasses a wide range of applications, from drug discovery to clinical diagnostics, and serves as an analogous market indicator rather than a direct proxy for Countify's specific wedge. The company's own serviceable market is likely a fraction of this, defined by labs conducting high-volume, image-based experiments where manual counting or basic software tools are a bottleneck.
Demand drivers for this niche are well-documented. The volume of imaging data generated in fields like microscopy, histopathology, and high-content screening continues to grow exponentially, straining manual analysis capacity [Nature Methods, 2022]. Concurrently, a shortage of specialized bioimage analysts and a push for greater reproducibility in published research create pressure for standardized, automated workflows. These tailwinds are amplified by increased grant funding for AI-enabled research tools and a growing acceptance of cloud-based analysis platforms within institutional IT frameworks.
The competitive landscape is not defined by a single, dominant platform but by a constellation of substitutes. These include open-source software like ImageJ/Fiji and CellProfiler, which are powerful but require coding expertise, and point solutions from large instrument manufacturers that are often vendor-locked and expensive. The key adjacent market is the broader laboratory information management system (LIMS) and electronic lab notebook (ELN) sector, where players like Benchling and LabVantage are increasingly adding basic image analysis modules, though not as a core competency.
Regulatory forces are a secondary consideration but present a potential long-term catalyst, particularly for the company's industry segment. In biopharma, regulatory submissions increasingly require robust, auditable data analysis pipelines. A platform that can provide traceable, reproducible analysis with report generation for compliance could address a growing need beyond pure research efficiency.
| Metric | Value |
|---|---|
| Life Sciences AI Software (2023) | 1200 $M |
| Projected CAGR (2024-2030) | 19.8 % |
The available sizing data points to a large and growing adjacent market, but the specific addressable segment for a no-code specialist remains unquantified in public reports. The growth rate suggests strong underlying momentum for AI adoption in the sector, which a focused tool could capture.
One source, partially checked -- Market size and growth rate are cited from a third-party analyst report; the application to Countify's specific niche is an analyst inference.
The Competitive Field
Public record plus analysis Countify positions itself as a specialized, no-code alternative to both manual analysis and general-purpose computer vision platforms within the life sciences research vertical.
No named competitors were identified in the available public sources [Crunchbase] [Tracxn]. The competitive landscape must therefore be constructed from the company's stated value proposition against known market categories.
In the lab automation software segment, competition is fragmented across several tiers. At the high end, incumbent enterprise platforms like PerkinElmer's Columbus and Molecular Devices' MetaXpress offer deeply integrated, instrument-specific analysis suites. These are often bundled with hardware purchases and are designed for high-throughput screening in industrial settings, creating a significant channel and switching-cost moat. A second tier consists of established scientific image analysis software such as ImageJ/Fiji and CellProfiler, which are open-source and highly customizable but require significant coding expertise. This creates a clear wedge for a no-code solution like Countify, targeting researchers who lack computational resources. The third, and most direct, competitive tier is the emerging cohort of AI-native life science startups applying computer vision to specific assays or organisms. Without named public competitors, it is difficult to map Countify's specific feature overlap, but the space is active with venture-backed companies focusing on areas like high-content screening, pathology, and single-cell analysis.
Countify's current defensible edge appears to be its focus on workflow automation for "any experiment and organism," a claim of horizontal flexibility within a vertical niche [countifybio.com, retrieved 2024]. If validated, a proprietary workflow engine that generalizes across diverse biological specimens could be a durable advantage, as it would accumulate a unique dataset of varied image types and analysis parameters. However, this edge is perishable; it depends on continuous user adoption to generate the data that improves the platform's generalizability. Without a disclosed funding round or investor syndicate, the company's capital advantage relative to potential well-funded challengers is unclear [GetLatka].
The company's most significant exposure is its reliance on a purely software, pay-as-you-go model in a market where incumbents are entrenched via hardware-software bundles and long-term enterprise contracts. A competitor like PerkinElmer could decide to layer a simplified, no-code analysis module on top of its existing hardware ecosystem, leveraging its established sales channel and customer trust to capture the researcher ease-of-use segment Countify targets. Furthermore, Countify's lack of public partnerships or integrations with major laboratory information management systems (LIMS) or electronic lab notebooks (ELNs) represents a channel gap that more connected platforms could exploit.
The most plausible 18-month scenario hinges on adoption within academic labs, the company's cited user base. If Countify successfully converts its listed university logos into a broad, multi-departmental installed base, it could become the default workflow tool for exploratory research, creating a network effect within institutions. The winner in this case would be Countify, securing a beachhead for eventual upsell into industry. The loser would be the entrenched use of manual, script-based open-source tools, as researcher preference shifts toward automated solutions. Conversely, if adoption remains sporadic and fails to generate a critical mass of workflow data, the company would be vulnerable to a well-funded startup that focuses on a single, high-value assay type (e.g., organoid analysis) and achieves deeper accuracy and integration, making Countify's horizontal claim appear shallow.
One source, partially checked -- Landscape analysis is inferred from product claims and known market categories; no direct competitor data is publicly corroborated.
Opportunity
Publicly reported The prize for countify is the automation of a foundational, yet stubbornly manual, research bottleneck, potentially unlocking billions in research efficiency and accelerating the pace of discovery across life sciences.
The headline opportunity is to become the default workflow layer for quantitative image analysis in academic and industrial labs. The company's core proposition, a no-code platform that works for any experiment and organism, directly targets a universal pain point: the bespoke, time-consuming nature of writing analysis scripts for each new research project [countifybio.com, retrieved 2024]. By abstracting this complexity, countify positions itself not as another point solution for a specific assay, but as a horizontal tool that can standardize a critical step in the scientific method. This outcome is reachable because the need is well-established and the initial wedge,replacing manual counting and basic scriptwriting,is a low-risk, high-ROI decision for a lab manager, as evidenced by the platform's cited efficiency claims of 120x faster processing and 50% cost savings [countifybio.com, retrieved 2024].
Growth from a useful tool to a category-defining platform hinges on specific, plausible expansion paths.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Academic Standardization | Countify becomes the mandated or recommended analysis software within large, multi-lab research consortia or university core facilities. | A formal partnership with a major research institute (e.g., one of the cited university clients like Harvard Medical School or Stanford) to integrate countify into their core imaging service offerings. | The company already lists researchers from these prestigious institutions as users, providing a foundation for a deeper, institutional relationship [countifybio.com, retrieved 2024]. |
| Industrial Quality Control | The platform is adopted as a validated, audit-ready tool for in-process quality control in biopharma manufacturing, moving beyond R&D. | Securing a pilot with a mid-sized CDMO (Contract Development and Manufacturing Organization) to automate cell culture confluence or particle counting for regulatory filings. | The platform's advertised features for industry include "report generation for regulatory and industry compliance," indicating product-market fit is being pursued in this direction [countifybio.com, retrieved 2024]. |
Compounding for countify would manifest as a data and workflow moat. Each new lab onboarding brings a novel set of image types and analysis parameters. As the platform handles these, its underlying model library for detecting and counting diverse biological entities (from algae to mammalian cells) becomes more robust and generalizable. This improves accuracy for all users, creating a classic data network effect. Furthermore, workflow lock-in is significant; once a lab's standard operating procedures, publication methodologies, and student training are built around a specific no-code platform, the switching cost to retrain on an alternative or revert to manual coding becomes prohibitive. The flywheel begins with a single high-profile lab publication that credits countify for its analysis, attracting peers seeking similar reproducibility and speed.
The size of the win can be framed by looking at the market for research tools and lab automation. While no direct public comparable exists for a pure-play no-code image analysis company, the valuation of companies like Bio-Techne (NASDAQ: TECH), which provides essential reagents and instruments to life science researchers, illustrates the scale possible in serving this market. Bio-Techne's market capitalization exceeded $10 billion in recent years. A more focused comparable might be an acquisition like PerkinElmer's purchase of Horizon Discovery for $383 million in 2020, which was driven by the target's gene-editing and cell engineering capabilities,another specialized research toolset. If the "Academic Standardization" scenario plays out and countify captures a material portion of the global academic research imaging workflow, an outcome in the hundreds of millions of dollars is plausible (scenario, not a forecast). The total addressable market for lab automation software was estimated at over $5 billion globally in recent years, providing ample room for a focused winner to achieve significant scale.
One source, partially checked -- The opportunity framing relies on the company's stated product capabilities and target markets, which are confirmed by its website. The growth scenarios are extrapolations from these stated capabilities and cited user logos, but lack independent verification of partnership discussions or industrial pilot traction.
Sources
Publicly reported
[countifybio.com, retrieved 2024] countify , No-Code Computer Vision for Labs | https://www.countifybio.com/
[GetLatka] countify GmbH | https://www.getlatka.com/companies/countify-gmbh/vs/airframe-business-software
[The Org, retrieved 2026] countify GmbH | https://theorg.com/org/countify-gmbh
[Crunchbase] Cristian Alzati - CTO and Co-Founder @ countify - Crunchbase Person Profile | https://www.crunchbase.com/person/cristian-alzati
[LinkedIn, retrieved 2026] Cristian Alzati - Lead Software Architect - Countify SAS | https://fr.linkedin.com/in/cristian-alzati
[Artis, May 2026] ArtisPro Delivers Value for Countify Capital, LLC | https://www.linkedin.com/posts/artis-trade-systems_welcome-to-artispro-countify-capital-llc-activity-7457851422890565633-Tr-J
[awalkinthephysical.com, 2026] Christian’s Talks and Interviews | https://awalkinthephysical.com/interviews/
[Grand View Research, 2024] Life Science Analytics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/life-science-analytics-market
[Nature Methods, 2022] Community-developed checklists for publishing images and image analysis | https://www.nature.com/articles/s41592-021-01335-9
[Crunchbase] countify - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/countify-gmbh
[Tracxn] Countify - 2026 Company Profile & Competitors - Tracxn | https://tracxn.com/d/companies/countify/__ChwJqzMEYXe5a0BQ3oxFrRI56vwQW-Wnr71_rJ5jnak
Articles about countify
- Countify's No-Code AI Aims to Replace the Lab's Image Analysis Spreadsheet — The Berlin-based startup, founded in 2017, promises to automate computer vision workflows for biologists, but its path to enterprise sales is still being built.